Uncategorized

Asieris Announces Positive Phase III Bridging Trial of Hexvix®, a Diagnostic Drug for Bladder Cancer

Asieris Pharmaceuticals, a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the Phase III bridging clinical trial of Hexvix® for bladder cancer diagnosis met the primary endpoint.

Asieris Announces Positive Phase III Bridging Trial of Hexvix®, a Diagnostic Drug for Bladder Cancer Read More »

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) – August 11, 2023

Mirum Pharmaceuticals, Inc. announced that on August 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 34,200 shares of common stock and 17,100 restricted stock units to six new employees under Mirum’s 2020 Inducement Plan.

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) – August 11, 2023 Read More »

Scroll to Top